Savings Offer

Help your eligible, commercially-insured patients pay as little as $4 per 30-day fill for brand-name LYRICA. 

For more information on the Savings Offer, click here.

*Eligibility required. Terms and conditions apply. Full terms and conditions can be found at LYRICA.com/co-pay-savings-card. This Savings Offer will be accepted only at participating pharmacies. This Savings Offer is not health insurance. No membership fees. Maximum savings per year is $3,000. Patient must have private insurance. This Savings Offer is not valid for cash-paying patients. This Savings Offer is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs. This Savings Offer is not valid for prescriptions that are eligible to be reimbursed in whole by private insurance plans or other health or pharmacy benefit programs. Viatris reserves the right to revoke, rescind, or amend this offer without notice. For further information, call 1-866-954-1475, visit LYRICA.com, or write: Viatris, 1000 Mylan Boulevard, Canonsburg, PA 15317.

LYRICA is a registered trademark of Viatris Specialty LLC, a Viatris Company.

LYR-2022-1530 V2

Dosing & Administration

 

  • For adult indications, begin dosing at 150 mg/day. For partial-onset seizure dosing in pediatric patients 1 month of age and older, refer to section 2.4 of the PI.
  • Dosing recommendations:
  • Dose should be adjusted in adult patients with reduced renal function.

LYRICA is available in doses ranging from 25 mg to 300 mg and as a 20 mg/mL oral solution.

LYRICA is a registered trademark of Viatris Specialty LLC, a Viatris Company.

LYR-2022-1530 V2

Help Keep Rx As Prescribed

To help ensure the brand you prescribe is dispensed as written at the pharmacy, write "Dispense as Written" (DAW)*, as appropriate, on your next LYRICA prescription.

*Prescription language and requirements may vary based on your state's law.

LYRICA is a registered trademark of Viatris Specialty LLC, a Viatris Company.

LYR-2022-1530 V2